{"id":"NCT03879863","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","officialTitle":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-16","primaryCompletion":"2019-10-04","completion":"2019-10-04","firstPosted":"2019-03-19","resultsPosted":"2025-01-23","lastUpdate":"2025-01-23"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%) QID","otherNames":[]},{"type":"DRUG","name":"Vehicle Ophthalmic Solution QID","otherNames":[]},{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%) QID to BID","otherNames":[]},{"type":"DRUG","name":"Vehicle Ophthalmic Solution QID to BID","otherNames":[]}],"arms":[{"label":"Reproxalap Ophthalmic Solution (0.25%) QID","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic Solution QID","type":"PLACEBO_COMPARATOR"},{"label":"Reproxalap Ophthalmic Solution (0.25%) QID to BID","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic Solution QID to BID","type":"PLACEBO_COMPARATOR"}],"summary":"The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease","primaryOutcome":{"measure":"Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))","timeFrame":"The efficacy assessment period (Day 1 through 85) was assessed at Weeks 1, 2, 4, 6, 8, 10, and 12; baseline was Day 1.","effectByArm":[{"arm":"Reproxalap Ophthalmic Solution (0.25%) QID","deltaMin":-11.5,"sd":2.44},{"arm":"Vehicle Ophthalmic Solution QID","deltaMin":-15,"sd":2.39},{"arm":"Reproxalap Ophthalmic Solution (0.25%) QID to BID","deltaMin":-17.8,"sd":2.2},{"arm":"Vehicle Ophthalmic Solution QID to BID","deltaMin":-6.8,"sd":2.12}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":105},"commonTop":["General disorders and administration site conditions"]}}